PHATHOM PHARMACEUTICALS INC

Phathom Pharmaceuticals tackles GI disease with cutting‑edge therapies, trading at $12.16 on Nasdaq – see its growth potential despite a negative P/E ratio.

Phathom Pharmaceuticals has received a 10-year FDA exclusivity extension for its drug Voquezna, protecting it from generic competition until 2032.

Phathom Pharmaceuticals Inc. is navigating a mixed bag of financial and strategic developments, with promising product pipeline and market positioning efforts offset by financial challenges and shifting investor sentiment.